TGFB1 and idiopathic interstitial pneumonia: The small interfering RNA (siRNA) SRN‐001, which targets amphiregulin, a downstream fibrosis regulator induced by TGF‐β, is currently undergoing a phase I clinical trial for IPF treatment (NCT05984992).